Michael Bruckman

Dr. Bruckman is the CEO & COO for Haima Therapeutics after joining in 2018. Mike oversees the company’s business operations and execution of SynthoPlate’s technical development and grant funding strategies. Mike is a seasoned scientist with over 16 years of experience engineering nanoparticles for applications in technology and medicine. Prior to joining Haima, Mike led the commercialization efforts to commercialize a saliva glucose sensor for diabetics as Direct of Research at the technology development startup company, NanoBio Systems. He has 23 publications, 2 book chapters, and 3 patents.

Dr. Bruckman obtained his Ph.D. in organic chemistry from the University at South Carolina and received additional training in Biomedical Engineering and medical device commercialization at CWRU and the Naval Research Laboratory.